News
Nivolumab-AVD outperforms BV-AVD in efficacy and safety, offering a promising frontline option for OAs with advanced classic ...
A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results